|Bid||0.00 x 1100|
|Ask||0.00 x 1200|
|Day's range||15.80 - 16.27|
|52-week range||7.30 - 20.55|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.80|
On a per-share basis, the New York-based company said it had a loss of 69 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Levi & Korsinsky announces it has commenced an investigation of Stemline Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
On a per-share basis, the New York-based company said it had a loss of 93 cents. For the year, the company reported that its loss widened to $67.8 million, or $2.94 per share. Revenue was reported as $898,000. ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...